Company
Management Team
Science Advisory Board
Lab Licensure
|
|
Mansoor Mohammed, Ph.D.
President and CEO |
Dr. Mohammed is a recognized world leader in genome and microarray technologies and is a frequent keynote speaker both nationally and internationally. Dr. Mohammed received his Ph.D. degree with a double major in molecular immunology and molecular genetics from the University of Guelph, Canada. He completed postdoctoral training at the University of California, Los Angeles, first in the department of molecular immunology and genetics and then as a clinical fellow in cytogenetics. Dr. Mohammed then continued his clinical cytogenetics training at Baylor college of Medicine, Houston and was appointed Director of Research and Development at Spectral Genomics Inc., Houston where he was instrumental in pioneering the first commercially available whole genome BAC array. After developing the microarray CGH platform at Spectral Genomics Inc. and establishing an extensive international network of collaborative research and development, Dr. Mohammed was recruited by Quest Diagnostics Incorporated, North America’s largest clinical reference laboratory where he was the Director of the department of Advanced Technologies. He is the holder of multiple patents in the fields of molecular immunology and genomic microarray technologies. In addition to his role at CMDX, Dr. Mohammed serves as an ambassador of sciences to the Toronto Genome Center, of the renowned Toronto Hospital for Sick Kids. |
|
Shelly Gunn, M.D., Ph.D.
Medical Director |
Dr. Gunn earned her B.A. and Masters degrees from Trinity University, and a Ph.D. in genetics from the University of Texas Health Science Center at San Antonio (UTHSCSA) Graduate School of Biomedical Sciences. Her doctoral work focused on the detection of cryptic chromosomal abnormalities in pediatric patients with normal cytogenetics and central nervous system dysmyelination. She went on to earn an M.D. from the UTHSCSA Medical School where she also completed her internship and residency in Clinical Pathology, and now serves as Clinical Assistant Professor in the Department of Pathology. While at UTHSCSA, Dr. Gunn was the recipient of the Association for Molecular Pathology’s Young Investigator Award for outstanding research, and the Klein Award for the “most outstanding report illustrating the correlation of clinical medicine, pathology, and pathophysiology.” She has published papers and abstracts related to array-based comparative genomic hybridization (array CGH) and has been a featured speaker at various scientific meetings and symposia. Her current translational research interest is the development of array CGH based clinical assays for scanning tumor genomes in hematological malignancies.
|
|
Dindy Ramkissoon
VP of Sales and Marketing |
In 1980 Dindy launched his career in Cytogenetics under the leadership of world renowned Cytogeneticist Dr. T.C. Hsu at MD Anderson Cancer Center in Houston. He co-authored several publications with Dr. Hsu and was assigned on major projects such as Agent Orange Chromosome Breakage Study of Vietnam Veterans and NASA Chromosome Breakage Baseline Study. In 1987, Dindy joined Perceptive Systems Inc which later became Perceptive Scientific Instruments (PSI), one of the pioneering companies to develop and manufacture Image Analysis Systems for Cytogenetics testing. Dindy was the North America Sales Manager when Applied Imaging acquired the company in 2000. At Applied Imaging, Dindy managed the National Accounts in North America, the Distributors in Mexico and Latin America plus the Power Gene product Business Unit winning both quarterly and national awards. In 2002 he joined Cyberonics, an implantation device company that treats epilepsy and major depression, as their Southern Area Accounts Manager. During his four years with Cyberonics he won many regional and national awards including two years President Club. following his years at Cyberonics, Dindy joined Applied Spectral-Imaging (ASI). Dindy left ASI as US Sales Manager, and joined CMDX in 2007. In 1980 Dindy graduated from Winona State University in Minnesota with a BA degree in Biology.
|
|
Mercedes Gorre, Ph.D.
VP of Scientific Affairs |
Dr. Gorre received her bachelor’s degree from Harvard University and earned her Ph.D. in Molecular Biology from the Molecular Biology Institute at the University of California, Los Angeles. Her doctoral work focused on drug resistance mechanisms and surrogate assay development for leukemia. She and her colleagues were the first to discover point mutations and gene amplifications that confer drug resistance to Gleevec in Chronic Myelogenous Leukemia patients. Her postdoctoral work at the David Geffen School of Medicine at UCLA focused on developing strategies to overcome drug resistance through the use of alternative small molecule therapies as well as studying the role of kinase domain mutations in oncogenic potency. Dr. Gorre’s work has been published in several scientific journals including Science, The Proceedings of the National Academy of Sciences, Cancer Cell, Blood, and Clinical Cancer Research. She is a holder of patents in the field of drug resistance, has served as an invited speaker at national and international conferences on targeted therapies for cancer and is a referee for peer-reviewed scientific and medical journals. Prior to joining CMDX, Dr. Gorre was the Principal Scientist of Hematopathology at the Nichols Institute of Quest Diagnostics Incorporated, North America’s largest clinical reference laboratory.
|
|
Robert Embree
VP of Operations |
Robert brings over 15 years of experience in the clinical laboratory industry to the company. Prior to joining CMDX, he served as Managing
Director of Global IHC and image analysis for US LABS. Prior to joining US LABS, Robert held various management
positions in a number of Southern California laboratories, including United Vet Labs, Lakewood Pathology, and Central Medical Laboratories. Robert has been
the recipient of several awards for leadership, innovation, productivity and implementation. He is a licensed histotechnologist and holds a qualification
in immunohistochemistry from the American Society for Clinical Pathology (ASCP). Robert received his B.S. degree from the University of Redlands in Southern
California. |
|
